BLK enters August at $1,131, up 3% on the week and 13.6% over the past month, riding a wave of post-earnings analyst upgrades — yet insiders, including founder and CEO Larry Fink, sold heavily into that strength just days after the Q2 beat.
The Street's reaction to Q2 was unusually unified. Every analyst action in the aftermath was an upgrade or a target raise — no cuts, no downgrades. JPMorgan's Kenneth Worthington made the biggest move, lifting his rating from Neutral to Overweight and pushing his target from $1,165 to $1,364 on July 16. Morgan Stanley's Mike Cyprys went further, raising to $1,488. BofA, UBS, Barclays, Evercore, BMO, and KBW all followed with target increases, clustering in the $1,245–$1,488 range. The mean Street target now sits at $1,313.50 — implying roughly 16% upside from the current price, a healthy but not frenzied premium. Factor scores reinforce the bullish tilt: EPS forward momentum ranks in the 96th percentile across the universe, analyst recommendation divergence is in the 91st, and dividend score at the 87th percentile points to income quality. The bear case centres on cost pressures — G&A up over 13% in 2025 and operating margins being revised down — though the bulls counter with $13.5 trillion in AUM and organic base fee growth running above the company's own 5% target.
What makes the setup genuinely interesting is what the insiders did on the same day those upgrades landed. On July 16 — the day JPMorgan upgraded and the rest of the Street raised targets — CEO Fink sold 1,905 shares at roughly $1,080 for about $2.1 million. Chief Legal Officer Christopher Meade sold over 18,000 shares across two transactions that day, netting more than $19.9 million combined. In April, Fink sold an additional 34,000 shares across four tranches near $1,050, totalling roughly $35.6 million. Net insider activity over the past 90 days amounts to a sale of approximately 62,639 shares worth $66.8 million. These are not trivial filings — Fink's July sale alone carries a significance score, and the timing, right as the Street turned more bullish, is the tension worth watching.
The lending and positioning picture is almost the opposite of interesting — which is itself informative. Short interest runs at just 1.4% of the free float, barely changed on the week. Borrow costs have fallen sharply, now running at 0.40% versus highs above 0.90% in early July, and availability is effectively uncapped, with over 154 million shares available to borrow against roughly 2.1 million shares short. Options sentiment has drifted mildly more constructive: the put/call ratio eased to 0.94, about 1.5 standard deviations below its 20-day average of 0.97, near the low end of its 52-week range. There is no short-side pressure here, no squeeze setup, no defensive hedging spike. The positioning looks entirely comfortable.
The earnings history adds one note of caution. BLK's Q2 print on July 15 drove a 6% one-day gain — the stock added another 3% over the following five days. But the prior quarterly event produced a 3% one-day decline and a 2.9% five-day loss. With no next earnings date yet confirmed in the snapshot, the relevant question heading into the back half of the year is whether the margin and cost trajectory can keep pace with what an unusually constructive analyst consensus has now priced in — and whether insider selling at current levels reflects a different view of that trajectory than the Street is currently taking.
See the live data behind this article on ORTEX.
Open BLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
